TABLE 3

Results of all regression analysis and 90-day estimates for primary and secondary outcomes

Effectiveness outcomes90-day change from baselineRegression sample sizeAdjusted group difference95% confidence intervalp-value
myCOPD#Usual care
Primary outcomes
 CAT score−1.8 (5.76)0.0 (5.54)58MD: −1.27−4.47–1.920.435
 ≥1 inhaler error−0.3 (0.70)0.1 (0.71)54OR: 0.300.09–1.060.061
 Average inhaler errors−0.3 (1.61)−0.1 (1.20)54IRR: 0.970.52–1.810.928
Secondary outcomes
 PAM score−0.7 (14.28)−3.5 (13.07)58MD: −0.98−8.22–6.26
 PAM level0.1 (0.83)−0.3 (0.70)54OR: 1.650.46–5.85
 SEAMS1.0 (0.00)0.0 (−3.00)58MD: 0.33−2.22–2.87
 EQ5D score0.1 (0.23)0.0 (0.18)54MD: −0.04−0.12–0.05
 EQ5D VAS62.0 (21.35)60.9 (19.92)53MD: 0.86−9.46–11.18
 Exacerbations0.2 (1.28)0.2 (0.72)60IRR: 2.551.17–5.54
 Activity level (mean daily steps)226.8 (5680.38)11 915.9 (37 447.87)13MD: −2252.94−10 433.77–5927.88
 Smoking−0.0 (0.20)−0.0 (0.33)53OR: 0.760.07–7.89
 Cessation2 (6.9)3 (9.7)16OR: 0.600.04–9.09

All regression models included adjustment for baseline values, COPD severity and centre. n in 90-day observed outcome is defined as participants who were at the final study visit. CAT: COPD assessment test; MD: mean difference; OR: odds ratio; IRR: incidence rate ratio; PAM: patient activation measurement; SEAMS: self-efficacy for appropriate medication use scale; EQ5D: EuroQol 5 dimensions; EQ5D VAS: EuroQol 5 dimensions visual analogue scale. #: n=24; : n=30. Example interpretation: MD – A difference of −1.27 means after adjustment for baseline values, COPD severity and centre the mean CAT score was 1.27 lower in myCOPD. IRR – A difference of 0.97 means after adjustment for baseline values, COPD severity and centre the rate of average inhaler errors for myCOPD was 0.97 times the rate of average inhaler errors for usual care. OR – A difference of 0.30 means after adjustment, the odds of ≥1 inhaler error in myCOPD were 0.30 times the odds of ≥1 inhaler error in usual care.